NOV 12, 2015 10:30 AM PST

Validation of Mass Spec Analytical Platforms and Proteomic Biomarkers: FDA perspective

Speaker
  • Scientific Reviewer, Food and Drug Administration Center for Devices and Radiological Health
    Biography
      Senior Staff Fellow, Office of In Vitro Diagnostics and Radiological Health, Food and Drug Administration Center for Devices and Radiological Health.
      I received a Bachelor of Science degree in biology from the Massachusetts Institute of Technology and a Ph.D. in biochemistry from the University of California, San Francisco. Before working at the FDA, I worked at the Novartis Institutes of Biomedical Research performing basic research in oncology target discovery.

    Abstract

    Basic research in Proteomics has led to new understanding of proteins’ contributions to health and disease, and has also driven the advancement of powerful analytical technologies used to explore these contributions.  Translating these discoveries and technologies into in vitro diagnostic (IVD) tests presents expanded opportunities to improve patient care; however, the complexity of these technologies raises challenging questions on how to evaluate the safety and effectiveness of these tests.  Fundamental to using IVDs in the clinic is the demonstration that the tests are safe and effective—that the results claimed are accurate and precise and that the clinical interpretation of the results is supported by science.  The more complex the information gathered, the more challenging is the validation of results; therefore,  FDA will discuss the elements of clinical and analytical validation of IVDs and proteomic technologies the successful transfer of research and discovery-level assays into the clinic.


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    JUN 09, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    Loading Comments...
    Show Resources